Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia Academic Article uri icon


MeSH Major

  • Molecular Chaperones
  • Multiprotein Complexes
  • Neoplasms


  • © 2018 Ferrata Storti Foundation. Acute myeloid leukemia carries a dismal prognosis in older patients. The objective of this study was to investigate the safety and efficacy of decitabine combined with the CXCR4 antagonist plerixafor in newly diagnosed older patients with acute myeloid leukemia and to evaluate the effects of plerixafor on leukemia stem cells. Patients were treated with monthly cycles of decitabine 20 mg/m2days 1-10 and escalating doses of plerixafor (320-810 mcg/kg) days 1-5. Sixty-nine patients were treated, with an overall response rate of 43%. Adverse karyotype did not predict response (P=0.31). Prior hypomethylating agent treatment was the strongest independent predictor of adverse overall survival (hazard ratio 3.1; 95%CI: 1.3-7.3; P=0.008) and response (14% in previously treated patients, 46% in treatment naïve; P=0.002). As expected, the most common toxicities were myelosuppression and infection. Plerixafor induced mobilization of leukemia stem and progenitor cells, but did not cause clinically significant hyperleukocytosis. Reduction in leukemia stem cells appeared to correlate with duration of response. Plerixafor can be safely added to decitabine in poor-prognosis, elderly acute myeloid leukemia patients. The maximum tolerated dose of the combination was 810 mcg/kg. While mobilization of leukemia stem cells was observed in some patients, the clinical benefit of adding plerixafor was uncertain. This trial was registered at identifier: 01352650.

publication date

  • July 31, 2018



  • Academic Article



  • eng

PubMed Central ID

  • PMC6068018

Digital Object Identifier (DOI)

  • 10.3324/haematol.2017.183418

PubMed ID

  • 29724902

Additional Document Info

start page

  • 1308

end page

  • 1316


  • 103


  • 8